Who are Saxagliptin + Metformin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DPP-4 inhibitor + metformin group, alogliptin and actoplus met, Sitagliptin + Metformin, Saxagliptin plus metformin IR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/saxagliptin-metformin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Saxagliptin + Metformin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Saxagliptin + Metformin (Saxagliptin + Metformin) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor + biguanide combination. Area: Diabetes.

marketed DPP-4 inhibitor + biguanide combination DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and AMPK Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Saxagliptin + Metformin (Saxagliptin + Metformin) — AstraZeneca. Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while metformin reduces hepatic glucose production and improves insulin sensitivity.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Saxagliptin + Metformin TARGET	Saxagliptin + Metformin	AstraZeneca	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and AMPK
DPP-4 inhibitor + metformin group	DPP-4 inhibitor + metformin group	Beni-Suef University	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
alogliptin and actoplus met	alogliptin and actoplus met	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
Sitagliptin + Metformin	Sitagliptin + Metformin	Baylor College of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
Saxagliptin plus metformin IR	Saxagliptin plus metformin IR	AstraZeneca	phase 3	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin (AMPK pathway)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor + biguanide combination class)

AstraZeneca · 2 drugs in this class
Baylor College of Medicine · 1 drug in this class
Beni-Suef University · 1 drug in this class
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Saxagliptin + Metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/saxagliptin-metformin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab